DE69820465T2 - Liposomen-umschlossene polynukleotidzusammensetzung sowie verfahren - Google Patents

Liposomen-umschlossene polynukleotidzusammensetzung sowie verfahren Download PDF

Info

Publication number
DE69820465T2
DE69820465T2 DE69820465T DE69820465T DE69820465T2 DE 69820465 T2 DE69820465 T2 DE 69820465T2 DE 69820465 T DE69820465 T DE 69820465T DE 69820465 T DE69820465 T DE 69820465T DE 69820465 T2 DE69820465 T2 DE 69820465T2
Authority
DE
Germany
Prior art keywords
liposomes
polynucleotide
lipid
solvent
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69820465T
Other languages
German (de)
English (en)
Other versions
DE69820465D1 (de
Inventor
M. Theresa ALLEN
Darrin Stuart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Application granted granted Critical
Publication of DE69820465D1 publication Critical patent/DE69820465D1/de
Publication of DE69820465T2 publication Critical patent/DE69820465T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69820465T 1997-06-23 1998-06-22 Liposomen-umschlossene polynukleotidzusammensetzung sowie verfahren Expired - Fee Related DE69820465T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5049097P 1997-06-23 1997-06-23
US50490P 1997-06-23
PCT/US1998/012937 WO1998058630A1 (en) 1997-06-23 1998-06-22 Liposome-entrapped polynucleotide composition and method

Publications (2)

Publication Number Publication Date
DE69820465D1 DE69820465D1 (de) 2004-01-22
DE69820465T2 true DE69820465T2 (de) 2004-09-16

Family

ID=21965541

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69820465T Expired - Fee Related DE69820465T2 (de) 1997-06-23 1998-06-22 Liposomen-umschlossene polynukleotidzusammensetzung sowie verfahren

Country Status (11)

Country Link
US (1) US6120798A (https=)
EP (1) EP1017365B1 (https=)
JP (1) JP2002508765A (https=)
AT (1) ATE255882T1 (https=)
AU (1) AU7983798A (https=)
CA (1) CA2294579C (https=)
DE (1) DE69820465T2 (https=)
DK (1) DK1017365T3 (https=)
ES (1) ES2212305T3 (https=)
TW (1) TWI225412B (https=)
WO (1) WO1998058630A1 (https=)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5855911A (en) * 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
US7309692B1 (en) * 1996-07-08 2007-12-18 Board Of Regents, The University Of Texas System Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1
US6977244B2 (en) * 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US20030229040A1 (en) * 1997-03-21 2003-12-11 Georgetown University Cationic liposomal delivery system and therapeutic use thereof
US6126965A (en) * 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
US7262173B2 (en) * 1997-03-21 2007-08-28 Georgetown University Chemosensitizing with liposomes containing oligonucleotides
US6559129B1 (en) * 1997-03-21 2003-05-06 Georgetown University Cationic liposomal delivery system and therapeutic use thereof
US7285288B1 (en) 1997-10-03 2007-10-23 Board Of Regents, The University Of Texas System Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US7704962B1 (en) 1997-10-03 2010-04-27 Board Of Regents, The University Of Texas System Small oligonucleotides with anti-tumor activity
CA2361551A1 (en) * 1999-02-08 2000-08-10 Alza Corporation Method for controlling liposome size
US7223406B2 (en) * 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
US6852323B2 (en) 2000-07-21 2005-02-08 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
US20020146829A1 (en) * 2000-11-29 2002-10-10 Aventis Pharmaceuticals Products Inc. Neutral and anionic colloidal particles for gene delivery
US6610322B1 (en) * 2000-12-20 2003-08-26 Brian Charles Keller Self forming, thermodynamically stable liposomes and their applications
US20030077829A1 (en) * 2001-04-30 2003-04-24 Protiva Biotherapeutics Inc.. Lipid-based formulations
KR100411234B1 (ko) * 2001-08-14 2003-12-18 한국과학기술원 올리고뉴클레오티드 혼성화 미셀 및 그의 제조방법
CA2471967A1 (en) * 2002-01-03 2003-07-31 Board Of Regents, The University Of Texas System Wt1 antisense oligos for the inhibition of breast cancer
KR100466254B1 (ko) * 2002-02-25 2005-01-14 한국과학기술원 세포내 전달을 위한 올리고뉴클레오티드와 친수성 고분자로 구성되는 유전자 전달용 접합체, 고분자 전해질 복합 미셀 및 그의 제조방법
WO2003097805A2 (en) 2002-05-15 2003-11-27 California Pacific Medical Center Delivery of nucleic acid-like compounds
US20030219696A1 (en) * 2002-05-23 2003-11-27 Moreland Gerald W. Method and apparatus for preventing backflow in dental saliva evacuators
EP1530465B2 (en) * 2002-06-26 2015-12-16 MediGene AG Method of producing a cationic liposomal preparation comprising a lipophilic compound
US7901708B2 (en) 2002-06-28 2011-03-08 Protiva Biotherapeutics, Inc. Liposomal apparatus and manufacturing methods
AU2002953285A0 (en) * 2002-12-12 2003-01-02 Protech Research Pty Ltd Yeast treatment
US8052966B2 (en) 2003-04-21 2011-11-08 University Of Southern California Methods and compositions for treating metastatic cancer
US20070178066A1 (en) 2003-04-21 2007-08-02 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
DK2072040T3 (da) * 2004-05-12 2013-07-29 Baxter Healthcare Sa Terapeutisk anvendelse af nukleinsyremikrokugler
WO2006133022A2 (en) 2005-06-03 2006-12-14 The Johns Hopkins University Compositions and methods for decreasing microrna expression for the treatment of neoplasia
US20070087045A1 (en) * 2005-10-14 2007-04-19 Industrial Technology Research Institute Lipid carrier and method of preparing the same
WO2007080902A1 (ja) 2006-01-11 2007-07-19 Kyowa Hakko Kogyo Co., Ltd. 眼球において標的遺伝子の発現を抑制する組成物および眼球における疾患の治療剤
EP2639315A1 (en) 2007-05-11 2013-09-18 The Johns Hopkins University Biomarkers for melanoma
PL208054B1 (pl) * 2007-09-06 2011-03-31 Akademia Medyczna Im Piastow Śląskich We Wrocławiu Kompozycja lipidowa do wytwarzania lipidowego nośnika dla leków genetycznych i jej zastosowanie
CA2710983A1 (en) * 2007-12-27 2009-10-01 The Ohio State University Research Foundation Lipid nanoparticle compositions and methods of making and using the same
US20110229498A1 (en) 2008-05-08 2011-09-22 The Johns Hopkins University Compositions and methods for modulating an immune response
EP2319519B1 (en) 2008-08-01 2016-01-27 Kyowa Hakko Kirin Co., Ltd. Composition for inhibiting expression of target gene
EP2408917A2 (en) 2009-03-19 2012-01-25 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF BTB AND CNC HOMOLOGY 1, BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR 1 (BACH 1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) SEQUENCE LISTING
EP2408458A1 (en) 2009-03-19 2012-01-25 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010107952A2 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2408915A2 (en) 2009-03-19 2012-01-25 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20120004281A1 (en) 2009-03-27 2012-01-05 Merck Sharp & Dohme Corp RNA Interference Mediated Inhibition of the Nerve Growth Factor Beta Chain (NGFB) Gene Expression Using Short Interfering Nucleic Acid (siNA)
JP2012521764A (ja) 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いた胸腺間質性リンパ球新生因子（ＴＳＬＰ）遺伝子発現のＲＮＡ干渉媒介性阻害
AU2010229847A1 (en) 2009-03-27 2011-10-13 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of the intercellular adhesion molecule 1 (ICAM-1)gene expression using short interfering nucleic acid (siNA)
WO2010111471A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2012521760A (ja) 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたアポトーシスシグナル調節キナーゼ１（ＡＳＫ１）遺伝子発現のＲＮＡ干渉媒介性阻害
JP4912510B2 (ja) 2009-08-31 2012-04-11 ナノキャリア株式会社 粒子組成物及びこれを有する医薬組成物
JP4653242B1 (ja) 2010-02-12 2011-03-16 ナノキャリア株式会社 粒子状医薬組成物
US20110237686A1 (en) 2010-03-26 2011-09-29 Cerulean Pharma Inc Formulations and methods of use
JP5902616B2 (ja) 2010-04-28 2016-04-13 協和発酵キリン株式会社 カチオン性脂質
US20130129811A1 (en) 2010-04-28 2013-05-23 Takeshi Kuboyama Cationic lipid
MX354217B (es) 2010-05-14 2018-02-19 Dana Farber Cancer Inst Inc Composiciones y metodos para el tratamiento de leucemia.
WO2011143651A1 (en) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating metabolism
CA2805265A1 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
WO2012024170A2 (en) 2010-08-17 2012-02-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2012027206A1 (en) 2010-08-24 2012-03-01 Merck Sharp & Dohme Corp. SINGLE-STRANDED RNAi AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER
WO2012027467A1 (en) 2010-08-26 2012-03-01 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF PROLYL HYDROXYLASE DOMAIN 2 (PHD2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
JP5952197B2 (ja) 2011-01-19 2016-07-13 協和発酵キリン株式会社 標的遺伝子の発現を抑制する組成物
JP2013095755A (ja) 2011-11-02 2013-05-20 Kyowa Hakko Kirin Co Ltd カチオン性脂質
AU2012340086A1 (en) 2011-11-17 2014-05-29 The Regents Of The University Of California Therapeutic RNA switches compositions and methods of use
EP2780455B1 (en) 2011-11-17 2017-07-05 The U.S.A. as represented by the Secretary, Department of Health and Human Services Auto-recognizing therapeutic rna/dna chimeric nanoparticles (np)
CA2858694A1 (en) 2011-12-12 2013-06-20 Kyowa Hakko Kirin Co., Ltd. Lipid nano particles comprising combination of cationic lipids
TWI594767B (zh) 2011-12-12 2017-08-11 協和醱酵麒麟有限公司 含有陽離子性脂質之藥物傳遞系統用脂質奈米粒子
CA2860731C (en) 2012-01-10 2023-02-28 M. Mahmood Hussain Method of treating hyperlipidemia and atherosclerosis with mir-30c
HK1206644A1 (en) * 2012-03-29 2016-01-15 Shire Human Genetic Therapies, Inc. Lipid-derived neutral nanoparticles
US9750819B2 (en) 2012-05-23 2017-09-05 Ohio State Innovation Foundation Lipid nanoparticle compositions and methods of making and methods of using the same
US10502737B2 (en) 2012-05-25 2019-12-10 The University Of Vermont And State Agriculture College Anti-thrombotic compositions and methods for assaying platelet reactivity and treatment selection
TW201726600A (zh) 2012-07-06 2017-08-01 協和醱酵麒麟有限公司 陽離子性脂質
SG11201502954TA (en) 2012-07-16 2015-05-28 Kyowa Hakko Kirin Co Ltd Rnai pharmaceutical composition for suppressing expression of kras gene
JP6000033B2 (ja) * 2012-09-18 2016-09-28 株式会社ピカソ美化学研究所 内包物質に耐熱性を与えたリポソーム及びその製造方法
ES2703341T3 (es) 2013-03-14 2019-03-08 Genvivo Inc Ensayo diagnóstico de timidina quinasa para aplicaciones de terapia génica
EP3158992A1 (en) * 2015-10-21 2017-04-26 Universität Heidelberg Liposomes containing cell penetrating peptides and tetraetherlipids for the oral delivery of macromolecules
IL289849B2 (en) 2015-11-10 2024-01-01 Nat Inst Biotechnology Negev Ltd Means and methods for reducing tumorigenicity of cancer stem cells
EP3386594B1 (en) 2015-12-11 2023-05-03 The General Hospital Corporation Combination of a platelet-derived growth factor receptor alpha inhibitor and a histone lysine demethylase inhibitor for treating drug-tolerant glioblastoma
US10525138B2 (en) 2015-12-25 2020-01-07 Kyowa Hakko Kirin Co., Ltd. Compound as cationic lipid
AU2019247490A1 (en) 2018-04-06 2020-10-22 Children's Medical Center Corporation Compositions and methods for somatic cell reprogramming and modulating imprinting
EP3628309A1 (en) 2018-09-28 2020-04-01 Universität Heidelberg Method of making oral dosage forms
CN115135764A (zh) * 2019-12-31 2022-09-30 弗莱德哈钦森癌症中心 用于刺激和维持治疗部位处的免疫系统应答性的纳米颗粒系统
JP2023530234A (ja) 2020-06-05 2023-07-14 ザ・ブロード・インスティテュート・インコーポレイテッド 新生物を治療するための組成物および方法
WO2022053130A1 (en) 2020-09-09 2022-03-17 Sid Alex Group, S.R.O. Antago-mir-155 for treatment of v-src, c-src-tyrosine kinase-induced cancers
CN118660710A (zh) 2021-10-20 2024-09-17 罗切斯特大学 用于年龄相关白质损失的竞争性治疗的分离神经胶质祖细胞
WO2024163747A2 (en) 2023-02-02 2024-08-08 University Of Rochester Competitive replacement of glial cells
WO2024226499A1 (en) 2023-04-24 2024-10-31 The Broad Institute, Inc. Compositions and methods for modifying fertility
WO2025090427A1 (en) 2023-10-23 2025-05-01 University Of Rochester Glial-targeted relief of hyperexcitability in neurodegenerative diseases
WO2025096975A1 (en) 2023-11-02 2025-05-08 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods of enhancing immune cell therapies by runx2 modulation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) * 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
ATE285477T1 (de) * 1995-06-07 2005-01-15 Inex Pharmaceutical Corp Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer
US5705385A (en) * 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
WO1997004748A2 (en) * 1995-08-01 1997-02-13 Advanced Therapies, Inc. Enhanced artificial viral envelopes for cellular delivery of therapeutic substances
US5855911A (en) * 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
FR2751222B1 (fr) * 1996-07-16 1998-10-09 Capsulis Compositions contenant au moins un acide nucleique et leurs applications dans le domaine biomedical, en particulier en therapie genique

Also Published As

Publication number Publication date
ES2212305T3 (es) 2004-07-16
ATE255882T1 (de) 2003-12-15
DK1017365T3 (da) 2004-03-29
CA2294579C (en) 2007-10-09
CA2294579A1 (en) 1998-12-30
TWI225412B (en) 2004-12-21
US6120798A (en) 2000-09-19
JP2002508765A (ja) 2002-03-19
DE69820465D1 (de) 2004-01-22
HK1025906A1 (en) 2000-12-01
WO1998058630A1 (en) 1998-12-30
AU7983798A (en) 1999-01-04
EP1017365B1 (en) 2003-12-10
EP1017365A1 (en) 2000-07-12

Similar Documents

Publication Publication Date Title
DE69820465T2 (de) Liposomen-umschlossene polynukleotidzusammensetzung sowie verfahren
DE69630691T2 (de) Liposomal p-Ethoxy Oligonucleotides
DE69633669T2 (de) Verfahren zur zelltransfektion mit liposomal-verkapselten nukleinsäuren
DE60126801T2 (de) Lipidformulierungen zur zielgerichteten abgabe
DE69906977T2 (de) In liposomen verkapselte nukleinsäurekomplexe
DE69708919T2 (de) Neue liposomkomplexe mit erhöhter systemischer verabreichung
DE69624801T2 (de) Stabile arzneistoffabgabekomplexe mit lipiden und verfahren zu deren herstellung
DE69634084T2 (de) Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer
DE69409361T2 (de) Herstellung von liposomen und verfahren zur substanzverkapselung
DE69718924T2 (de) Fusogene liposomzusammensetzung und verfahren
DE69505677T2 (de) Liposomales verabreichungssystem für biologisch aktive stoffe
DE68929382T2 (de) Liposomen
DE69826488T2 (de) Stabile partikuläre komplexe lamellarer struktur mit neutraler oder negativer gesamtladung
DE69414709T2 (de) Liposomale antisense methylphosphonat oligo-nukleotide und verfahren zu deren herstellung sowie deren verwendung
US6835395B1 (en) Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles
DE69631149T2 (de) Formulierungen in form von emulsionen zur verabreichung von nukleinsäuren an zellen
DE69837339T2 (de) Veränderung der Wirkstoffladung in multivesikulären Liposomen
DE69535540T2 (de) Zusammensetzung enthaltend nukleinsäuren und kationische polymere, zubereitung und verwendung
DE69837274T2 (de) Verfahren zur verkapselung von nukleinsäuren in lipiddoppelschichten
DE60014133T2 (de) Lipid zur Verwendung in einer Liposomzusammensetzung zur Abgabe eines Mittels an eine Zelle
DE69633725T2 (de) Kationische lipide/dns komplexe zum zielen von genen
DE69837819T2 (de) Kondensierte plasmid-liposome komplex zur transfektion
DE60036861T2 (de) Verkapselung biologisch aktiver komplexe in liposomen
AU773515B2 (en) Method for controlling liposome size
DE69429511T2 (de) Reduzierung von durch liposome induzierte physiologischen gegenreaktionen

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: ALZA CORP., MOUNTAIN VIEW, CALIF., US

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee